Allogeneic CD19/BCMA-targeted CAR-γδT cell injection
IIT2026017
Phase 1 mab active
Quick answer
Allogeneic CD19/BCMA-targeted CAR-γδT cell injection for Refractory/Relapsed Systemic Lupus Erythematosus is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Refractory/Relapsed Systemic Lupus Erythematosus
- Phase
- Phase 1
- Modality
- mab
- Status
- active